Welcome to our dedicated page for Im Cannabis news (Ticker: IMCC), a resource for investors and traders seeking the latest updates and insights on Im Cannabis stock.
IM Cannabis Corp. (Nasdaq: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany. The IM Cannabis news feed on Stock Titan aggregates company-issued press releases and other coverage related to its operations, strategy, governance, and capital markets activity.
Readers can expect frequent corporate updates, such as board and management changes, including appointments and departures of directors and executive officers. These announcements often detail the backgrounds of new appointees and outline how governance changes fit within the company’s broader strategic review.
The news stream also features financial reporting items, including notices about upcoming earnings releases and press releases summarizing interim financial results. These communications may discuss revenue trends, gross margin, non-IFRS measures such as Adjusted EBITDA, and commentary on factors affecting performance in Israel and Germany.
Another key category of coverage involves strategic and transactional developments. IM Cannabis has reported on initiatives to identify additional business opportunities, the signing of a non-binding term sheet to acquire a majority stake in a quantum computing bio data company, and its evaluation of potential expansion into the United States cannabis market, as well as possible divestitures of its German and Israeli operations. Capital markets updates, such as warrant amendments, resale registration statements, and Nasdaq listing compliance notices, are also part of the company’s news flow.
For investors and observers tracking IMCC, this page offers a centralized view of how the company communicates its progress in medical cannabis markets, its strategic review, and its responses to regulatory and market conditions. Users who follow IM Cannabis can use this news feed to monitor developments over time and review the company’s own descriptions of its plans and performance.
IM Cannabis Corp. (NASDAQ: IMCC), a prominent medical cannabis company operating in Israel and Germany, has scheduled its first quarter 2025 financial results announcement for Thursday, May 15th, 2025, before market opening. The company will host a zoom conference at 9:00 AM ET on the same day to discuss the results and conduct a Q&A session with investors. Those unable to attend can access a recording on the company's investor relations website within 24 hours after the call.
IM Cannabis Corp. (NASDAQ: IMCC) has received a notification from Nasdaq on April 9, 2025, indicating non-compliance with the minimum stockholders' equity requirement of US$2.5 million for continued listing. The company reported stockholders' equity of US$2,184,722, falling short of the requirement. IMCC has 45 days until May 26, 2025, to submit a compliance plan and may receive up to 180 days to regain compliance.
Additionally, the company announced plans to acquire the remaining 26% interest in Focus Medical Herbs through its subsidiary IMC Holdings. The purchase price was determined by an independent third party to be NIS 818,740, to be settled through the issuance of common shares. The transaction requires disinterested shareholders' approval at the upcoming annual general meeting on May 23, 2025.
IM Cannabis (NASDAQ: IMCC) reported strong Q4 and full-year 2024 results, marking significant operational improvements. The company achieved 25% revenue growth in Q4 compared to Q4 2023, with annual revenue increasing 11% to $54.0M.
Key highlights include a 183% revenue increase in IMC Germany to $15.5M in 2024, and a 42% reduction in operating expenses in Q4 2024. The company achieved a positive Adjusted EBITDA of $0.5M in Q4 2024, compared to losses of $4.3M in Q4 2023. Annual Adjusted EBITDA losses decreased by 87% to $1.1M in 2024.
Despite these improvements, the company faced challenges including a one-time inventory clearance of $3.8M and Oranim revocation expenses of $2.7M. Cash and cash equivalents stood at $0.9M as of December 31, 2024, down from $1.8M the previous year. The company's financial statements include a going concern note regarding its ability to continue operations.
IM Cannabis (CSE: IMCC) (NASDAQ: IMCC), a leading medical cannabis company operating in Israel and Germany, has scheduled its Fourth Quarter and Full Year 2024 financial results announcement for Monday, March 31, 2025, before market opening.
The company will host a zoom web conference at 9:00 AM ET on the same day to discuss the results, which will include a Q&A session for investors. A recording of the call will be made available on the company's investor relations website within 24 hours after the event.
IM Cannabis Corp. (NASDAQ: IMCC) (CSE: IMCC), a medical cannabis company operating in Israel and Germany, has announced a change in its auditors. The company has transitioned from Kost Forer Gabbay & Kasierer (Ernst & Young Global member) to Fahn Kanne & Co. Grant Thornton Israel, effective January 16, 2025.
The previous auditor resigned at the company's request, and the new appointment was made based on the audit committee's recommendation. The board of directors has appointed the new auditor until the next annual shareholders' meeting. The company confirms there were no reservations, modified opinions, or reportable events in the previous auditor's reports. All required documentation has been filed on SEDAR+ in accordance with National Instrument 51-102.
IM Cannabis Corp. (NASDAQ: IMCC) reported Q3 2024 financial results showing a 12% revenue increase to $13.9M compared to Q3 2023. The company achieved significant growth in Germany with 66% revenue increase to $5.8M. Operating expenses decreased by 16% to $4.1M, while the operational expense ratio improved by 25% to 30%. The company reduced its EBITDA loss by 68% to $0.5M and adjusted EBITDA loss by 82% to $0.2M. Average selling price per gram increased by 42% to $6.20, though total dried flower sales volume decreased to 2,202 kg.
IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC), a medical cannabis company operating in Israel and Germany, has announced it will release its third quarter 2024 financial results on November 14, 2024, before market opening. The company will host a zoom conference at 9:00am ET on the same day to discuss the results and conduct a Q&A session with investors. A recording of the call will be available on the company's investor website within 24 hours after the event.
IM Cannabis Corp. (NASDAQ: IMCC) (CSE: IMCC) has announced a non-brokered private placement offering of up to US$1,613,000 through the sale of approximately 625,000 units. Each unit consists of one common share and one share purchase warrant. The offering price will be based on the 10-day volume weighted average price of shares on the Canadian Securities Exchange preceding October 3, 2024.
The company's management team, including CEO Oren Shuster and director Shmulik Arbel, will lead the offering. Proceeds will be used to repay a loan to A.D.I. CAR ALARMS & STEREO SYSTEMS The closing is expected by November 11, 2024.
Additionally, IM Cannabis plans to settle a US$560,000 benefit related to personal loan guarantees provided by Mr. Shuster. The company has also cancelled 32,305 options and 142,784 share purchase warrants, while granting 32,305 new options to eligible persons.
IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) has announced outstanding preliminary Q3 2024 performance for its German subsidiary, Adjupharm GmbH (IMC Germany). The company reported a remarkable 50% increase in revenue compared to Q2, where IMC Germany sold about CAD$ 3.5M. This growth exceeds expectations and demonstrates IMC Germany's successful execution of strategic initiatives and strong market demand for its products.
The partial legalization of cannabis in Germany, which came into effect in April 2024, has significantly increased demand for cannabis products in pharmacies. IMC's CEO, Oren Shuster, emphasized that ensuring a robust supply chain to meet this increased demand was a key objective since April 1st. The preliminary 50% growth is seen as a testament to delivering on this objective.
FAQ
What is the current stock price of Im Cannabis (IMCC)?
What is the market cap of Im Cannabis (IMCC)?
